

Supplemental Online Content

Aaronson ST, van der Vaart A, Miller T, et al. Single-dose synthetic psilocybin with psychotherapy for treatment-resistant bipolar type II major depressive episodes: a nonrandomized controlled trial. *JAMA Psychiatry*. Published online December 6, 2023. doi:10.1001/jamapsychiatry.2023.4685

eTable 1. Participant Medication History and MADRS Outcomes

eTable 2. Correlations Across 5 Dimensions of the 5D-ASC, and with Endpoint MADRS

eFigure. Consort Diagram

This supplemental material has been provided by the authors to give readers additional information about their work.

ID	AD/AP trials	Mood stabilizer trials	ECT/TMS/ketamine	Total Tx Failures	Medication regimen – weaned prior to treatment	Medications restarted	Baseline MADRS	Week 3 MADRS	Endpoint MADRS
1	2	1	--	3	1 mood stabilizer	1 mood stabilizer (Week 4)	33	7	--
2	3	1	--	4	1 antidepressant 1 mood stabilizer 1 psychostimulant	1 psychostimulant (Week 5) 1 mood stabilizer (Week 5)	33	7	2
3	1	1	--	2	1 mood stabilizer 1 anxiolytic	--	36	6	1
4	3		TMS	4	1 antidepressant	1 antidepressant (Week 3)	31	19	9
7	4	2	--	6	1 antipsychotic 1 mood stabilizer	1 antipsychotic (Week 8) 1 mood stabilizer (Week 8)	31	8	5
8	3		--	3	1 psychostimulant 1 anxiolytic	--	31	2	2
9	3	2	--	5	1 mood stabilizer 1 antidepressant	--	35	3	0
10		2	--	2	2 mood stabilizers 1 neuropathic pain medication	--	31	5	1
11	3	1	ketamine	5	1 antidepressant 1 mood stabilizer 1 antipsychotic	1 antipsychotic (Week 2) 1 antidepressant (Week 4) 1 mood stabilizer (Week 11)	28	18	22
13	3	1	--	4	1 mood stabilizer 1 psychostimulant	--	39	6	2
14	2	1	--	3	1 antidepressant 1 mood stabilizer	1 antidepressant (Week 7) 1 mood stabilizer (Week 7)	22	16	0
15	5	1	--	6	1 antidepressant	--	33	0	0
16	3	1	ECT	5	1 antidepressant 1 psychostimulant	--	38	1	6
18	5		--	5	1 antidepressant 1 herbal supplement	--	19	0	0
19	5	2	--	7	1 antidepressant 1 mood stabilizer 1 antipsychotic	--	32	14	18

eTable 1. Medications and MADRS Outcomes. Participants treated in this study are listed by ID number. Number of prior medication trials in the antidepressant/antipsychotic (AD/AP) classes trialed prior to psilocybin are given in column 2. Total mood stabilizer (lamotrigine, lithium, divalproex) trials are shown in column 3. Only trials of sufficient time are included; historical medications which caused adverse reactions limiting duration to <5 weeks are not included. Column 4 indicates whether alternative interventions (ECT/TMS/ketamine) have been trialed. Column 5 summates all prior failed trials. Column 6 shows the regimen of medications by class at study start, weaned prior to treatment. Column 7 indicates which if any of these medications were restarted during the study period. Columns 8-10 list MADRS scores at baseline, week 3, and week 12 (endpoint) for reference.

		OB	AED	VR	AA	RV	Week 12 MADRS
Oceanic Boundlessness (OB)	Pearson Correlation	1	.725**	.933**	.889**	.794**	-.658**
	Sig. (2-tailed)		0.002	0.0000004	0.00001	0.0004	0.008
	N	15	15	15	15	15	15
Anxious Ego Dissolution (AED)	Pearson Correlation	.725**	1	.650**	.681**	.816**	-.550*
	Sig. (2-tailed)	0.002		0.009	0.005	0.0002	0.033
	N	15	15	15	15	15	15
Visionary Restructuralization (VR)	Pearson Correlation	.933**	.650**	1	.780**	.753**	-.789**
	Sig. (2-tailed)	0.0000004	0.009		0.001	0.001	0.000
	N	15	15	15	15	15	15
Auditory Alterations (AA)	Pearson Correlation	.889**	.681**	.780**	1	.788**	-0.505
	Sig. (2-tailed)	0.00001	0.005	0.001		0.0005	0.055
	N	15	15	15	15	15	15
Reduction of Vigilance (RV)	Pearson Correlation	.794**	.816**	.753**	.788**	1	-.587*
	Sig. (2-tailed)	0.0004	0.0002	0.001	0.0005		0.022
	N	15	15	15	15	15	15

** . Correlation is significant at the 0.01 level (2-tailed).

* . Correlation is significant at the 0.01 level (2-tailed).

eTable 2. Correlations Across 5 Dimensions of the 5D-ASC, and with Endpoint MADRS. The 5 dimensional subscales of the 5D-ASC show a high degree of inter-dimensional concordance. Each dimension also shows substantial degree ($r < -0.5$) of correlation with endpoint (Week 12) MADRS, reaching significance at $p < 0.05$ for 4 dimensions (Oceanic Boundlessness - OB, Anxious Ego Dissolution - AED, Visionary Restructuralization - VR, Reduction of Vigilance - RV).

eFigure. Consort Diagram

